We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+22.21%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$303M
AUM Growth
-$35.4M
Cap. Flow
-$54.1M
Cap. Flow %
-17.87%
Top 10 Hldgs %
52.11%
Holding
73
New
15
Increased
24
Reduced
14
Closed
16

Top Buys

1
RVNC
Revance Therapeutics, Inc.
RVNC
+$8.57M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.77M
3
ONC
BeOne Medicines Ltd
ONC
+$5.18M
4
AKRO
Akero Therapeutics
AKRO
+$3.9M
5
VIR icon
Vir Biotechnology
VIR
+$3.77M

Top Sells

1
AXSM icon
Axsome Therapeutics
AXSM
+$8.48M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$8.4M
3
PFE icon
Pfizer
PFE
+$8.16M
4
JNJ icon
Johnson & Johnson
JNJ
+$7.75M
5
TGTX icon
TG Therapeutics
TGTX
+$7.1M

Sector Composition

1 Healthcare 91.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
51
PTC Therapeutics
PTCT
$6.52B
$678K 0.22%
+16,675
New +$816K
ROIV icon
52
Roivant Sciences
ROIV
$24.8B
$645K 0.21%
+64,000
New +$572K
RAIN
53
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$390K 0.13%
325,000
+75,000
+30% +$375K
REPL icon
54
Replimune Group
REPL
$859M
$252K 0.08%
+10,865
New +$212K
VNDA icon
55
Vanda Pharmaceuticals
VNDA
$327M
$204K 0.07%
31,000
+18,500
+148% +$119K
MRSN
56
DELISTED
Mersana Therapeutics
MRSN
$202K 0.07%
+2,450
New +$358K
KYNB
57
Kyntra Bio
KYNB
$29.3M
$98.5K 0.03%
1,460
+400
+38% +$165K
ACRS icon
58
Aclaris Therapeutics
ACRS
$793M
– –
-425,000
Closed -$3.44M
ALT icon
59
CALL
Altimmune
ALT
$558M
– –
-400,000
Closed -$1.69M
APLS
60
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-51,900
Closed -$3.42M
ETNB
61
CALL
DELISTED
89bio
ETNB
– –
-100,000
Closed -$1.52M
ETNB
62
DELISTED
89bio
ETNB
– –
-200,000
Closed -$3.05M
GERN icon
63
Geron
GERN
$924M
– –
-450,000
Closed -$977K
IRON icon
64
Disc Medicine
IRON
$2.91B
– –
-100,000
Closed -$2.12M
JNJ icon
65
Johnson & Johnson
JNJ
$609B
– –
-50,000
Closed -$7.75M
KZR
66
DELISTED
Kezar Life Sciences
KZR
– –
-17,500
Closed -$548K
PFE icon
67
Pfizer
PFE
$143B
– –
-200,000
Closed -$8.16M
SRPT icon
68
CALL
Sarepta Therapeutics
SRPT
$1.82B
– –
-125,000
Closed -$17.2M
XFOR icon
69
X4 Pharmaceuticals
XFOR
$360M
– –
-28,333
Closed -$740K
RETA
70
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-300,000
Closed -$27.3M
ISEE
71
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-175,000
Closed -$4.26M
RXDX
72
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-15,000
Closed -$1.61M
CTIC
73
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-2,000,000
Closed -$8.4M
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Ghost Tree Capital held 73 positions worth $303M, down 10% from $338M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Ghost Tree Capital withdrew a net $54.1M in Q2 2023, closing 16 positions and reducing 14 holdings. Its most notable exit was CTI BioPharma Corp. (DE) Common Stock, an estimated $8.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 78% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in BeOne Medicines Ltd worth $4.01M.

  • Ghost Tree Capital's largest Q2 2023 buy was BeOne Medicines Ltd: 22,500 shares worth $4.01M.
  • Ghost Tree Capital added most to Revance Therapeutics, Inc. in Q2 2023, an estimated $8.57M increase.
  • Ghost Tree Capital's biggest Q2 2023 reduction was Axsome Therapeutics, cutting an estimated $8.48M.
  • Ghost Tree Capital fully exited CTI BioPharma Corp. (DE) Common Stock in Q2 2023, selling an estimated $8.4M.
  • Ghost Tree Capital's ten largest holdings make up 52% of its $303M portfolio in Q2 2023.
  • Ghost Tree Capital opened 15 new positions and closed 16 in Q2 2023.
  • Ghost Tree Capital's portfolio value fell 10% quarter-over-quarter to $303M.

Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.